Monday, July 4, 2016

BRIEF-Oryzon Genomics names new compound for preclinical development

* Names ORY-3001, a specific inhibitor of LSD1, as a

candidate for preclinical development for non-oncology

indications

Source text for Eikon:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)